α‐mangostin attenuates pristane‐induced lupus nephritis by regulating Th17 differentiation

Abstract

Thus, α-mangostin demonstrated its potential as a candidate therapeutic drug for LN and other Th17-mediated autoimmune diseases by inhibiting the function of Th17.